Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
FRTX was delisted on the 18th of December, 2023.
28 hedge funds and large institutions have $7.2M invested in Fresh Tracks Therapeutics, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 4 closing their positions.
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
23% more capital invested
Capital invested by funds: $5.87M → $7.2M (+$1.33M)
4% more funds holding
Funds holding: 27 → 28 (+1)
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$203K |
| 2 |
Renaissance Technologies
New York
|
+$144K |
| 3 |
New York State Common Retirement Fund
Albany,
New York
|
+$138K |
| 4 |
AI
Ariel Investments
Chicago,
Illinois
|
+$97.3K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$57K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$279K |
| 2 |
BlackRock
New York
|
-$79.7K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$76.8K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$67.3K |
| 5 |
Bank of New York Mellon
New York
|
-$26K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| $3K | +$2.19K | +3 | +300% |
|
27
UBS Group
Zurich,
Switzerland
| $2K | +$731 | +1 | +50% |
|
28
Citigroup
New York
| $1K | -$3.66K | -5 | -83% |
|
29
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
| – | -$26K | -38 | Closed |
|
|
30
Bank of New York Mellon
New York
| – | -$26K | -37 | Closed |
|
|
AG
31
Advisor Group
Phoenix,
Arizona
| – | -$2K | -3 | Closed |
|
FRTX Hedge Fund Activity: Q2 2017 in Review
28 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) for Q2 2017, worth a combined $7.2M — up 23% from $5.87M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new FRTX positions and 4 closed out — a net gain of 1 holder — while 8 added to existing stakes and 9 trimmed.
The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $203K. The largest seller was Vanguard Group, cutting an estimated $279K.
- 28 institutional investors held Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) as of Q2 2017, up from 27 in Q1 2017.
- Funds reported $7.2M of Fresh Tracks Therapeutics, Inc. Common Stock stock for Q2 2017, up 23% quarter-over-quarter.
- 5 funds opened new Fresh Tracks Therapeutics, Inc. Common Stock positions in Q2 2017 and 4 closed out, a net change of +1 holder.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock buyer in Q2 2017 was Bridgeway Capital Management, an estimated $203K added.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock seller in Q2 2017 was Vanguard Group, an estimated $279K sold.
Based on aggregated 13F filings for Q2 2017.